Myocardial infarction associated with erenumab: A case report. Issue 7 (8th June 2022)

• Record Type: Journal Article
• Authors: Perino, Justine; Corand, Virginie; Laurent, Elise; Théophile, Hélène; Miremont‐Salamé, Ghada; Pariente, Antoine; Colas, Jean‐Laurent; Couffinhal, Thierry; Salvo, Francesco
• Is Part Of: Pharmacotherapy. Volume 42:Issue 7(2022)
• Page Start: 585
• Page End: 589
• Publication Date: 2022-06-08
• Subjects: adverse event -- calcitonin gene‐related peptide -- case report -- drug safety -- migraine disorder -- pharmacovigilance; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1002/phar.2706
• Languages: English
• ISSNs: 0277-0008

Abstract

Abstract: Background: Monoclonal antibodies acting on the calcitonin gene‐related peptide or its receptor (CGRP‐mabs) are novel drugs for resistant migraine prophylaxis. As CGRP‐mabs cause inhibition of vasodilatation, their use is reserved to patients with no recent history of cardiovascular diseases. We report a case of myocardial infarction associated with erenumab. Case: A 57‐year‐old woman with a familial history of coronaropathy was first treated with erenumab 70 mg for 6 months and then increased to 140 mg. Almost 5 months after, the patient presented chest pain, increased troponin, and abnormal electrocardiogram. A myocardial infarction without coronarography abnormality was diagnosed through MRI. Conclusion: Further evidence is needed to assess the risk of myocardial infarction in patients treated with a CGRP‐mab. In patients over 40 years of age, the risk of coronary or cardiovascular events should be assessed using risk tables or algorithms to take into account cardiovascular risk factors. This may be complemented by appropriate examinations to measure the burden of coronary atherosclerosis, if necessary.